Insider sales at Adaptive Biotechnologies (NASDAQ: ADPT) include 122,523 RSUs

Rhea-AI Filing Summary

Adaptive Biotechnologies insider filing reports sales. The Form 144 lists 122,523 Restricted Stock Units to be sold with an effective date of 03/10/2026. The filing also details multiple sales by Julie Rubinstein between 03/03/2026 and 03/13/2026, showing individual trade sizes and proceeds.

Insights

Equity Compensation Specialist

Form 144 documents an insider disposition of RSUs and multiple open-market sales.

The filing lists 122,523 Restricted Stock Units with an indicated date of 03/10/2026. It also itemizes a sequence of sales by Julie Rubinstein on specific dates between 03/03/2026 and 03/13/2026, with per-trade share counts and gross proceeds shown.

Cash-flow treatment and whether proceeds go to the issuer or selling holder are not stated in the excerpt. Subsequent filings or broker confirmations would show execution method and final settlement details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	122523	1779033.96	153981561	03/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/10/2026	Restricted Stock Units	Issuer			122523	03/10/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/13/2026	19060	247017.60
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/12/2026	19060	245047.80
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/11/2026	19060	268364.80
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/10/2026	19460	285672.80
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/09/2026	30941	457617.39
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/06/2026	30941	468446.74
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/05/2026	30941	495056.00
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/04/2026	30941	513620.60
Julie Rubinstein 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	03/03/2026	30941	484751.21

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ADPT Form 144 show about RSUs?

The Form 144 lists 122,523 Restricted Stock Units with an effective date of 03/10/2026. The entry identifies the securities type as RSUs and shows the issuer label and the stated date associated with those units.

Who sold shares according to this filing for ADPT?

The filing records multiple open-market sales by Julie Rubinstein on dates between 03/03/2026 and 03/13/2026. Each sale line shows the number of shares and gross proceeds for that trade.

How many shares did Julie Rubinstein sell in these transactions?

The excerpt shows multiple trade entries, for example 30,941 shares on 03/03/2026 and 19,060 shares on 03/13/2026. Each line lists the specific share count and corresponding proceeds.

Are proceeds recipient details shown in the Form 144 excerpt?

The provided excerpt shows gross proceeds per sale (dollar amounts) but does not state who receives the proceeds or how they're applied. Cash‑flow treatment is not specified in the visible content.

Does the filing state total shares outstanding for ADPT?

The excerpt includes a numeric line 153,981,561 that appears near securities information and a date 03/11/2026. The filing text does not explicitly label that number as "shares outstanding" in the provided excerpt.